series-a
Stage
2
Investors
About
XXII, also known as 22nd Century Group, is a plant biotechnology company focused on tobacco harm reduction and cannabis research. They develop technologies to reduce nicotine in tobacco and modify cannabinoid profiles in cannabis.
Explore XXII's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.